Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?

authors

• Heng Marie Amélie
• Padovani Laetitia
• Dory-Lautrec Philippe
• Gentet Jean Claude
• Verschuur Arnaud
• Pasquier Eddy
• Figarella-Branger Dominique
• Scavarda Didier
• André Nicolas

document type

abstract

The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low- grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow- up of 23 months after the end of the bevacizumab–irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan–bevacizumab can improve progression-free survival in children with LGG.

more information